Skip to main content

Table 1 Potential targets and drugs against the interplay between cancer cells and adipocytes

From: Adipocytes: active facilitators in epithelial ovarian cancer progression?

Target Agent Mechanism Anti-cancer effect Reference
PPARγ GW9662 Suppression of adipocyte differentiation Inhibition of the anti-PD-L1 effect of adipocytes [106]
adipogenesis Sulforaphane Suppression of adipocyte differentiation Inhibition of the cancer promoting effect of adipocytes [111]
β-adrenergic Propranolol Suppression of lypolysis in adipocytes Inhibition of the EOC promoting effect of adipocytes [15]
lipid droplet Myricetin Suppression of the lipid droplets accumulation Inhibition of the EOC promoting effect of adipocytes [15, 112]
β-oxidation Trimetazidine Inhibition of fatty acid oxidation Inhibition of the EOC promoting effect of adipocytes [15, 113]
CD36 Sulfo-N-succinimidyl oleate Inhibition of fatty acid uptake of EOC cells Inhibition of the EOC progression and metastasis induced by adipocytes [114]
Leptin pegylated leptin peptide receptor antagonist 2 Leptin antagonist Inhibition of ovarian cancer peritoneal metastasis [115]
IL-6 Tocilizumab Monoclonal antibody against IL-6R Enhancement of the immunity in patients with recurrent EOC [116]
VEGF-A Bevacizumab Monoclonal antibody against VEGF-A Improvement of the survival in patients with ovarian cancer [81]